(19)
(11) EP 4 048 278 A1

(12)

(43) Date of publication:
31.08.2022 Bulletin 2022/35

(21) Application number: 20807558.0

(22) Date of filing: 20.10.2020
(51) International Patent Classification (IPC): 
A61K 31/5377(2006.01)
 A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61K 31/5377
(86) International application number:
PCT/US2020/056408
(87) International publication number:
WO 2021/080935 (29.04.2021 Gazette 2021/17)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 21.10.2019 US 201962924028 P

(71) Applicant: Celgene Corporation
Summit, NJ 07901 (US)

(72) Inventors:
  • ANTON, Maria Soraya, Carrancio
    San Diego, CA 92121 (US)
  • BUCHHOLZ, Tonia J.
    San Francisco, CA 94185 (US)
  • KASIBHATLA, Shailaja
    San Diego, CA 92121 (US)
  • LOPEZ-GIRONA, Antonia
    San Diego, CA 92121 (US)
  • NARLA, Rama, Krishna
    San Diego, CA 92121 (US)
  • POURDEHNAD, Michael
    San Francisco, CA 94185 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZ YL)AMINO)ISOINDOLINE-1,3-DIONE